IGC logo

IGC PHARMA INC

IGCNYSE AMERICAN
🏆 #4684 by market capUS Equity
$919.56▼ $33.38 (−3.63%)
Simulated price
🔔
Track IGC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.6%
7d▲ 320639.4%
14d▲ 344821.2%
30d▲ 312038.5%
ytd▲ 330201.7%
1y▲ 219417.8%
🏦Market Cap
$28M
Small Cap
📈Revenue Growth (YoY)
-6.7%
Declining
📊Gross Margin
21.9%
Moderate
💵FCF Margin
-543.4%
Thin
⚖️P/S Ratio
25.2x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$916.47 – $937.65
52-Week Range
$0.24 – $0.45
Volume
$3.01B
Avg Volume
$2.09B
Shares Outstanding
100.1M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$265,000
P/E Ratio
-3.4
P/S Ratio
25.2x
EPS (TTM)
$-0.08
Dividend Yield
0.00%
Dilution (1yr)
+5.6%

Why Investors Own IGC

  • ✓High-growth profile — revenue up +43.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 41% gross margin and 4% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IGC logo

IGC PHARMA INC

IGC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −6.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.7%▼ −39.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$10M▲ +37.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▲ +15.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
100.3M▲ +5.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$751K▼ −$2M YoY
StockOtter · stockotter.space

About IGC PHARMA INC

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$1,091.52
▲ +18.7% Upside
High Target$1,351.17
Low Target$845.21
Based on 25 analysts

Latest News & Updates

🚀
Barron’s·2h ago

IGC PHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift IGC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

IGC PHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.